Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 4/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | FABP7 | O15540 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515128 | 0.81 | TSHR (0.42) | CA1CA2TSHRIDO1DDB1 | |
| SCHEMBL29883515 | 0.81 | TSHR (0.42) | CA1CA2TSHRIDO1DDB1 | |
| SCHEMBL2367056 | 0.75 | FABP5 (0.48) | CA1CA2TSHRIDO1KMT2A | |
| SCHEMBL31532292 | 0.75 | FABP5 (0.48) | CA1CA2TSHRIDO1KMT2A | |
| SCHEMBL29618947 | 0.75 | FABP5 (0.48) | CA1CA2TSHRIDO1KMT2A | |
| SCHEMBL1056748 | 0.74 | TSHR (0.44) | TSHRIDO1DDB1CRBNHTR2A | |
| SCHEMBL8466835 | 0.73 | CASP3 (0.43) | KMT2A | |
| SCHEMBL6058496 | 0.73 | CASP3 (0.43) | KMT2A | |
| SCHEMBL4611910 | 0.72 | KMT2A (0.49) | TSHRKMT2ATDP1 | |
| SCHEMBL9204422 | 0.72 | KMT2A (0.43) | TSHRKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682540-A1 | AZOLIDINECARBONITRILES AND THEIR USE AS DPP-IV INHIBITORS | Sankaranarayanan, Alangudi (IN) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005033106-A1 | AZOLIDINECARBONITRILES AND THEIR USE AS DPP-IV INHIBITORS | SANKARANARAYANAN ALANGUDI (IN) | 2005-04-14 | — | — | WO | disclosed |
| US-20040106802-A1 | Novel compounds and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2004-06-03 | — | — | US | disclosed |
| EP-0819134-B1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES, METHOD FOR PREPARING SAME, AND SYNTHON USED THEREIN | GENSET SA (FR) | 2001-07-18 | — | — | EP | disclosed |
| US-6187913-B1 | Covalently crosslinked oligonucleotides, preparation method and synthon which is of use in the method | GENSET (FR) | 2001-02-13 | — | — | US | disclosed |
| EP-0819134-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES, METHOD FOR PREPARING SAME, AND SYNTHON USED THEREIN | GENSET SA (FR) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031523-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES, METHOD FOR PREPARING SAME, AND SYNTHON USED THEREIN | GENSET (FR) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106802-A1 | Novel compounds and therapeutic uses thereof | GPR119, SLC5A1, SLC2A3 | CA1 3323/4885CA2 2184/4885TSHR 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.